In a prospective study published this month, patients with cancer of unknown primary who were tested using BioTheranostics' CancerType ID assay, and who then received chemotherapy specific to their predicted tumor of origin, survived longer on average than expected for standard C
NEW YORK (GenomeWeb News) – Rosetta Genomics today said that Novitas, a designated Medicare contractor, has informed the firm that it plans to cover its miRview mets2 assay for all Medicare beneficiaries.
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Rosetta Genomics today said that the New York State Department of Health has granted the firm approval to begin processing patient samples from the state for its miRview mets^2 test.
In a document filed with the SEC, the Israeli firm disclosed that problems with a reagent used for testing could have affected results for about 100 miRview mets tests performed in the company's CLIA laboratory between August and October.